Dealmaking in Europe’s life sciences sector has been relatively muted in recent years, but the first half of 2025 has shown signs of strength as companies respond to the stark realities of an aging population. Faced with escalating long-term demand and increasingly stretched fiscal budgets, healthcare providers and pharmaceutical groups will depend on M&A to innovate, scale and adapt, with private equity sponsors joining in on the opportunity. The success of GLP-1 agonists, a new class of drugs for obesity and diabetes, has prompted a surge of investment and is proving to be a reliable M&A catalyst, as companies race to develop or acquire next-generation therapies and production capacities in this multibillion-dollar market.
Read the full article: Healthy Returns: European Life Sciences M&A Heats up as Sector Faces Demographic Reckoning //
Source: https://www.jdsupra.com/legalnews/healthy-returns-european-life-sciences-6275210/